Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/S584 enrolled

Overview

This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

584

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

liraglutideDRUG

insulin glargineDRUG

metforminDRUG

glimepirideDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * Treatment with oral anti-diabetic drugs for at least 3 months * HbA1c: 7.5-10.0 % (both incl.) in subjects on OAD monotherapy. 7.0-10.0 % (both incl.) in subjects on OAD combination therapy. * Body Mass Index (BMI) less than or equal to 45 kg/m2 Exclusion Criteria: * Treatment with insulin within the last 3 months * Treatment with any drug that could interfere with the glucose level * Any serious medical condition * Females who are pregnant, have intention of becoming pregnant or are breastfeeding

Locations (116)

Outcomes

Primary Outcomes

HbA1c

Time frame: after 26 weeks of treatment

Secondary Outcomes

body weight

Safety and tolerability

Beta-cell function

Glycaemic control

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.